> Atox Bio raised $30 million. The financing equips the Israeli biotech to complete a phase 2 trial in acute kidney injury and a phase 3 study in necrotizing soft tissue infections. Data from both trials are expected in 2019. Statement
> BioInvent and Transgene agreed to collaborate on an anti-CTLA-4 antibody to treat solid tumors. Release
> Scotland’s TC BioPharma struck a CAR-T deal with Bluebird Bio. Bluebird is paying $16 million upfront to work with the startup. The collaborators’ goals include the advancement of TC’s lead CAR-engineered gamma delta T cell program into human testing. Statement
> Advicenne raised €27 million in a Paris IPO. Release
> GenSight Biologics posted long-term data on its gene therapy treatment for Leber hereditary optic neuropathy. Statement (PDF)